Erica Schwartz’s confirmation gives the Centers for Disease Control and Prevention a permanent director after nearly a year without one—but it does not resolve the political fight over vaccines and scientific authority.

The Senate approved Schwartz by a roughly 51-44 vote, according to one account, while another reported the tally as 51-43. The result was largely partisan, with Virginia Democrat Tim Kaine the only Democrat supporting the nominee. The conservative framing emphasizes a Republican administration finally securing a leader for an agency battered by repeated confirmation failures and prolonged instability.¹

The liberal perspective stresses what Schwartz inherits: a CDC vacancy dating to former director Susan Monarez’s ouster after only 29 days, an acting leadership arrangement, and public-health concerns ranging from Ebola abroad to a domestic cyclosporiasis outbreak. Her background—as a retired Navy rear admiral, former deputy surgeon general and pandemic-response official—offers institutional credibility. She will also be the first Black woman to lead the agency.²

Yet both sides identify the same central test: whether Schwartz can operate independently while reporting to Health and Human Services Secretary Robert F. Kennedy Jr., whose skepticism toward vaccines has unsettled public-health officials. At her confirmation hearing, Schwartz said she “will never betray the science,” but largely avoided detailing how she would handle Kennedy. Republican committee chair Bill Cassidy demanded a director who would “stand up to crazy, stupid things being said that undermine faith in immunization.”³

That contrast defines Schwartz’s challenge. Conservatives see a qualified Trump nominee restoring order to a leaderless agency; liberals see a capable official entering an institution whose scientific credibility remains under political pressure. Confirmation fills the vacancy, but the harder question—who ultimately sets the CDC’s public-health line—remains open.